• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Omnicell Inc.

    5/15/26 7:06:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology
    Get the next $OMCL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Omnicell, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    68213N109

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    68213N109


    1Names of Reporting Persons

    Wellington Management Group LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,808,062.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,707,046.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,707,046.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP Number(s):
    68213N109


    1Names of Reporting Persons

    Wellington Group Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,808,062.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,707,046.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,707,046.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP Number(s):
    68213N109


    1Names of Reporting Persons

    Wellington Investment Advisors Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,808,062.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,707,046.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,707,046.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP Number(s):
    68213N109


    1Names of Reporting Persons

    Wellington Management Company LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,735,808.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,346,695.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,707,046.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Omnicell, Inc.
    (b)Address of issuer's principal executive offices:

    4220 North Freeway, Fort Worth TX 76137
    Item 2. 
    (a)Name of person filing:

    Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP Wellington Management Company LLP
    (b)Address or principal business office or, if none, residence:

    c/o Wellington Management Company LLP, 280 Congress Street, Boston MA 02210
    (c)Citizenship:

    Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware Wellington Management Company LLP - Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP Number(s):

    68213N109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the responses to Item 9 on the attached cover pages.
    (b)Percent of class:

    5.96  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    See the responses to Item 6 on the attached cover pages.

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    See the responses to Item 8 on the attached cover pages.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Not Applicable.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Wellington Group Holdings LLP - HC Wellington Investment Advisors LLP - HC Wellington Management Global Holdings, Ltd. - HC One or more of the following investment advisers (the "Wellington Investment Advisers"): Wellington Management Company LLP - IA Wellington Management Canada LLC - IA Wellington Management Singapore Pte Ltd - IA Wellington Management Hong Kong Ltd - IA Wellington Management International Ltd - IA Wellington Management Japan Pte Ltd - IA Wellington Management Australia Pty Ltd - IA The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Wellington Management Group LLP
     
    Signature:Matthew Revell
    Name/Title:Compliance Manager
    Date:05/15/2026
     
    Wellington Group Holdings LLP
     
    Signature:Matthew Revell
    Name/Title:Compliance Manager
    Date:05/15/2026
     
    Wellington Investment Advisors Holdings LLP
     
    Signature:Matthew Revell
    Name/Title:Compliance Manager
    Date:05/15/2026
     
    Wellington Management Company LLP
     
    Signature:Matthew Revell
    Name/Title:Compliance Manager
    Date:05/15/2026
    Get the next $OMCL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMCL

    DatePrice TargetRatingAnalyst
    2/4/2026$70.00Neutral → Buy
    BofA Securities
    1/8/2026$60.00Sector Weight → Overweight
    KeyBanc Capital Markets
    5/14/2025$35.00Equal Weight → Overweight
    Wells Fargo
    10/31/2024$44.00 → $57.00Buy → Neutral
    BofA Securities
    8/2/2024$26.00 → $39.00Underweight → Equal Weight
    Barclays
    1/3/2024$33.00Underweight
    Barclays
    11/3/2023$39.00 → $28.00Underweight → Equal Weight
    Wells Fargo
    11/3/2023Buy → Neutral
    BTIG Research
    More analyst ratings

    $OMCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bousa Edward Peter was granted 4,603 shares, increasing direct ownership by 26% to 22,589 units (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    6/3/26 4:05:19 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Director Scott Bruce E was granted 4,627 shares, increasing direct ownership by 20% to 27,600 units (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    6/3/26 4:05:19 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Director Seim Robin Gene was granted 4,845 shares, increasing direct ownership by 10% to 52,198 units (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    6/3/26 4:05:22 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN, PRESIDENT AND CEO Lipps Randall A bought $349,874 worth of shares (10,561 units at $33.13) and was granted 79,494 shares, increasing direct ownership by 28% to 413,104 units (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    3/18/25 4:13:27 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Omnicell upgraded by BofA Securities with a new price target

    BofA Securities upgraded Omnicell from Neutral to Buy and set a new price target of $70.00

    2/4/26 8:25:37 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Omnicell from Sector Weight to Overweight and set a new price target of $60.00

    1/8/26 8:12:33 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Omnicell from Equal Weight to Overweight and set a new price target of $35.00

    5/14/25 8:50:33 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

    Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, announced that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Tuesday, June 9, 2026, at 3:20 PM EDT. Live and archived webcasts of the presentation will be available through the Omnicell website at: https://ir.omnicell.com/events-and-presentations/ About Omnicell Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying

    6/2/26 4:01:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell to Present at the BofA Securities 2026 Healthcare Conference

    Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, announced that it will present at the BofA Securities 2026 Healthcare Conference on Tuesday, May 12, 2026, at 8:40 a.m. PDT. Live and archived webcasts of the presentation will be available through the Omnicell website at: https://ir.omnicell.com/events-and-presentations/ About Omnicell Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying automation and

    5/4/26 4:01:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer

    Newly established role strengthens understanding of healthcare clinician needs to help shape the Company's innovation priorities and portfolio decisions Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced that Rick Couldry has joined the Company as Senior Vice President, Chief Pharmacy and Clinical Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429498071/en/Omnicell Welcomes Rick Couldry to the Newly-Created Role of SVP, Chief Pharmacy and Clinical Officer In this newly created position, Couldry

    4/29/26 8:00:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    SEC Filings

    View All

    SEC Form SD filed by Omnicell Inc.

    SD - OMNICELL, INC. (0000926326) (Filer)

    5/29/26 4:04:15 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - OMNICELL, INC. (0000926326) (Filer)

    5/26/26 4:40:24 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    SEC Form SCHEDULE 13G filed by Omnicell Inc.

    SCHEDULE 13G - OMNICELL, INC. (0000926326) (Subject)

    5/15/26 7:06:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Leadership Updates

    Live Leadership Updates

    View All

    Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer

    Newly established role strengthens understanding of healthcare clinician needs to help shape the Company's innovation priorities and portfolio decisions Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced that Rick Couldry has joined the Company as Senior Vice President, Chief Pharmacy and Clinical Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429498071/en/Omnicell Welcomes Rick Couldry to the Newly-Created Role of SVP, Chief Pharmacy and Clinical Officer In this newly created position, Couldry

    4/29/26 8:00:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Appoints Baird Radford as Executive Vice President and Chief Financial Officer

    Seasoned leader brings more than 30 years of experience driving growth for healthcare and technology companies Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced the appointment of Baird Radford as Executive Vice President and Chief Financial Officer of the Company, effective August 26, 2025. Mr. Radford succeeds Nchacha Etta, who will be stepping down from the role, as announced earlier this year. Mr. Etta will remain with the Company in an advisory role through November 2025 to help ensure a smooth transition of responsibilities. This press release features multimedia. View the full release

    8/25/25 4:05:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer

    The Company taps business and operations executive with expertise that spans healthcare and med tech to help scale pharmacy automation and drive multi-year innovation and excellence Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240925324631/en/Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of Omnicell, effective October 7, 2024

    9/25/24 4:01:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Financials

    Live finance-specific insights

    View All

    Omnicell Announces First Quarter 2026 Financial Results

    Omnicell delivers strong first quarter 2026 financial results Raises full year 2026 non-GAAP EBITDA and non-GAAP EPS guidance Customer engagement underway for Omnicell Titan XT and OmniSphere Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today reported financial results for the first quarter ended March 31, 2026. First quarter results reflected strong execution across the business, supported by demand for Omnicell's connected device portfolio and solid performance across the Company's core points of care solutions. We believe that performance during the quarte

    4/28/26 6:30:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell to Release First Quarter 2026 Financial Results on April 28, 2026

    Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the first quarter 2026, before market open on Tuesday, April 28, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 9381205. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/event

    4/13/26 5:00:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Announces Fiscal Year and Fourth Quarter 2025 Financial Results

    Omnicell delivers solid fourth quarter 2025 financial results Announces major step toward autonomous medication management with the launch of its next generation dispensing system, Titan XT, at the American Society of Health-System Pharmacists (ASHP) 2025 Midyear Clinical Meeting & Exhibition Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced results for its fiscal year and fourth quarter ended December 31, 2025. "We finished 2025 with solid fourth quarter financial results, delivering full year 2025 total revenues, product booking

    2/5/26 6:30:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

    SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

    12/11/23 9:36:42 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

    SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

    9/11/23 1:33:44 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

    SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

    2/9/23 11:27:45 AM ET
    $OMCL
    Computer Manufacturing
    Technology